Rubisco Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.50 M
- Company Age 9 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.50 M
- Revenue Growth 53.33%
- Profit Growth 5.87%
- Ebitda 69.66%
- Net Worth 26.67%
- Total Assets 42.28%
About Rubisco Pharmaceuticals
Rubisco Pharmaceuticals Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 29 July 2015 (Nine years and six months 6 days old ). Its registered office is in Patna, Bihar, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹0.50 M.
Pinki Ray, Soniya Nigam, and Sangita Devi serve as directors at the Company.
Company Details
-
Location
Patna, Bihar, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230BR2015PTC024667
-
Company No.
024667
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
29 Jul 2015
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Patna
Industry
Who are the key members and board of directors at Rubisco Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pinki Ray
|
Director | 29-Jul-2015 | Current |
|
Soniya Nigam
|
Director | 29-Jul-2015 | Current |
|
Sangita Devi
|
Director | 08-Mar-2024 | Current |
Financial Performance of Rubisco Pharmaceuticals.
Rubisco Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 53.33% increase. The company also saw a slight improvement in profitability, with a 5.87% increase in profit. The company's net worth Soared by an impressive increase of 26.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rubisco Pharmaceuticals?
In 2023, Rubisco Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Nhse Private LimitedSoniya Nigam is a mutual person
-
Omachealthy Food Product Private Limited
Sangita Devi is a mutual person
-
Ras Manufacturing Industries Private Limited
Sangita Devi is a mutual person
-
Osthaes Private Limited
Sangita Devi is a mutual person
Charges (Loans)
₹0.50 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.05 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Mar 2017 | State Bank Of India | ₹0.50 M | Open |
How Many Employees Work at Rubisco Pharmaceuticals?
Rubisco Pharmaceuticals has a workforce of 13 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rubisco Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rubisco Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
